Evaluation of the BNT162B2 COVID-19 Vaccine in Children 5 to 11 Years of Age

Copyright

2022

Published By

Massachusetts Medical Society

This journal article details that a COVID-19 vaccination regimen consisting of two 10-μg doses of BNT162b2 administered 21 days apart was found to be safe, immunogenic, and efficacious in children 5 to 11 years of age.